CML Experts in Canada - Experts LMC au Canada
( Note: this list is not exhaustive)
CML Experts in Quebec - Experts LMC au Quebec
(Montreal - Quebec City - Sherbrooke)
(Montreal - Quebec City - Sherbrooke)
|
Hôpital Général Juif de Montréal
Hôpital Général Juif de Montréal Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Maisonneuve-Rosemont (Montréal) Hôpital Royal-Victoria (Montréal) Centre hospitalier universitaire de Sherbrooke Hôpital de l’Enfant-Jésus (Ville de Québec) CHU Pavillon Hôtel-Dieu de Québec (Québec) |
Vertical Divider
CML Experts in Ontario - Experts LMC en Ontario
|
Princess Margaret Hospital (Toronto)
Princess Margaret Cancer Centre (Toronto) Ottawa Hospital |
Vertical Divider
CML Experts in British Columia- Experts LMC en Colombie Britannique
Dr. Donna L. Forrest
Dr. John Shepherd
Dr. Kirk Schultz
Dr. David Sanford
CML Experts in Nova Scotia- Experts LMC en Nouvelle Écosse
Dr. Conrad Vincent Fernandez
Dr. Conrad Vincent Fernandez
Attention
To access this module, you need to get your CMLer's password. This password stay active for all the session on the website.
To access this module, you need to get your CMLer's password. This password stay active for all the session on the website.
Attention
Pour accéder aux liens ci-dessus, vous avez besoin du mot de passe du patient LMC, aussi appelé CMLer's Password. Ce mot de passe restera actif durant toute la session sur ce site web.
Pour accéder aux liens ci-dessus, vous avez besoin du mot de passe du patient LMC, aussi appelé CMLer's Password. Ce mot de passe restera actif durant toute la session sur ce site web.
CLINICAL TRIALS
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (Nova Scotia)
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (Nova Scotia)
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib ( British Columbia)
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (Novartis)
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) – (Novartis)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (British Colombia, Ontario, NovaScotia)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Treatment-free Remission Accomplished With Dasatinib in Patients With CML (Nova Scotia)
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia (Nova Scotia)
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib ( British Columbia)
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs (Novartis)
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) – (Novartis)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (British Colombia, Ontario, NovaScotia)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
ARTICLES
Health Canada approves two tests for CML patients
November 15, 2018, MDedge
Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia
December 2006, Current Oncology
Modes of access to the website
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
